Vantedge Medical  , a portfolio company of Aterian Investment Partners  , has acquired Hobson & Motzer, Inc.  Founded in 1912 and based in Connecticut, Hobson is a manufacturer of precision medical devices for the global surgical stapler market. Hobson’s sales stream is derived from medical consumables devices. The company’s facilities are highly automated and house a broad set of capabilities including progressive stamping, precision electrochemical machining, coined wire as well as leading tool and die capabilities. Hobson represents the fifth medical technology add-on acquisition for Vantedge since 2018.

According to a release from Hobson, the acquisition further strengthens Vantedge’s position as a nationwide manufacturing partner to blue-chip medical OEMs and broadens Vantedge’s consumable portfolio offering. Since Aterian’s acquisition of Vantedge in May 2018, Vantedge has acquired five medical technology businesses, established and fully commercialized new production facilities, completed substantial capital equipment capacity expansion and significantly invested in human capital throughout the organization. Vantedge now operates nine facilities across the United States with more than 1,200 employees.

“I have worked with the Hobson & Motzer team for many years, and they consistently delivered best-in-class quality, service, value, and innovation," says Brian King, Vantedge Medical, chairman and CEO. “Their depth and scale of capabilities, backed by over 100 years of experience, perfectly complements the existing Vantedge capabilities, enhances the value we bring to the world’s leading medical technology companies, and amplifies the difference we are making in the lives of patients and their families.”

Greg Santorno, Vantedge Medical’s chief commercial officer says that the union with Hobson & Motzer provides an expanded capability set that significantly increases the value it can deliver to its customers. "Providing additional device content enables supply chain simplification, risk reduction, collaborative innovation, and accelerated time to market,” he says. “The addition of precision progressive die stamping, unique value-add machining and assembly technologies, and a deep expertise in the manufacturing of surgical stapler anvils, complements our existing strengths serving the robotic assisted surgery, surgical instrumentation, orthopedics, ophthalmology, dental, drug-delivery, and medical diagnostics markets.”

“As I contemplated transitioning the company to new ownership, my key requirements were to find a company that shared our commitment to quality, service and innovation, had deep experience in the medtech space, and viewed our capabilities as enablers for growth,” says added Bruce Dworak, president/owner of Hobson & Motzer. “Vantedge Medical met these criteria in every way. I look forward to the continuing legacy of performance and market leadership, just at a much larger scale.”

Brandon Bethea, co-founder and partner of Aterian says the transaction allows Vantedge to take the next significant step in its strategic development. “Vantedge continues to evolve as a differentiated, scaled and expanding medical technology supplier into the industry’s most attractive OEMs across a variety of manufacturing disciplines and treatment modalities. The human health technologies that Vantedge serves on behalf of its customers change lives for the better, and in certain circumstances, save them. It is a privilege to wake up every day and work alongside Vantedge, and through Vantedge, our customers, he says.

Weil Gotshal & Manges LLP  advised Aterian on the legal aspects of this transaction.